GlassScriptPhysician profile
Michelle Mcclure
NPI 1982791760
$1,391.88
in general payments reported to CMS, 2019-2025
11 companies · $630 in 2025
The $630 reported for 2025 was more than what 77% of Nurse Practitioner providers received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $115 · 2024: $647 · 2025: $630.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,392.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,391.88 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $248.82 | 2024-2025 | Livdelzi |
| Novo Nordisk INC | $237.68 | 2024 | Wegovy |
| Genzyme Corporation | $146.18 | 2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.19 | 2025 | Caplyta |
| Sanofi-Aventis U.S. LLC | $122.74 | 2024 | |
| Pulmonx Corporation | $114.99 | 2023 | Pulmonx Chartis Tablet Console, Chartis Catheter, Zephyr Endobronchial Valve |
| Sanofi Pasteur INC. | $107.17 | 2024 | |
| Qol Medical, LLC | $102.10 | 2025 | Sucraid |
| Alk-Abello, INC | $79.71 | 2025 | Odactra |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $54.11 | 2025 | Relistor |
| Coloplast Corp | $49.19 | 2024 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Mcclure listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.